Lupus & antiphospholipid syndrome
Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil
Authors' conclusion
The PCV13-priming PPSV23-boost strategy in adults with SLE induced greater antibody responses for most immunogenicity outcomes than those elicited by the PPSV23/PCV13 strategy.
Study context
- Population
- Pneumococcal vaccine-naive adults (18 years or older) with systemic lupus erythematosus (SLE), single-center cohort in Brazil16 evaluable at T2
- Participants
- 34 adults
- Comparison
- Pneumococcal conjugate vaccine (PCV13) priming then pneumococcal polysaccharide vaccine (PPSV23) boost vs PPSV23 then PCV13
- Primary endpoint
- Immunogenicity for the 12 shared serotypes: ApAb GMC, FI-ApAb, overall seroprotection rate (1.3 μg/mL) and overall seroconversion rate
- Follow-up
- T2 (4-6 weeks after the booster dose)
Methodological detailslongitudinal, open-label, quasi-randomized, single-center, Screened between April 2019 and January 2020
- Longitudinal
- Open-label
- Quasi-randomized
- Single-center
- Screened between April 2019 and January 2020
Primary result
As reported in the abstract
FI-ApAb, overall seroconversion and seroprotection rates; ApAb GMC · 4-6 weeks after each pneumococcal vaccination
- PCV13/PPSV23 yielded significantly better FI-ApAb, overall seroconversion rate and overall seroprotection rate than PPSV23/PCV13
- Trend toward augmented ApAb GMC with PCV13/PPSV23
Safety
Safety of sequential pneumococcal vaccination
- No relevant safety issues identified
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil. Lupus. Published 27 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →